Summary of research into the consequences of the Ebola outbreak for children and communities in Liberia and Sierra Leone
This study describes the range of impacts that Ebola has had on children and families in Liberia and Sierra Leone, looking beyond the immediate health effects
Fact Book on WHO Level I and Level II monitoring indicators - To monitor the progress of efforts to improve the global medicines situation, WHO has developed a system of indicators that measure important aspects of a country’s pharmaceutical situation. Level 1 indicators measure the existence and ...performance of key national pharmaceutical structures and processes. Level II indicators measure key outcomes of these structures and processes in the areas of access, product quality and rational use. These indicators can be used to assess progress over time; to compare situations between countries; and to reassess and prioritize efforts based on the results.
This Fact Book gives the results of the assessment of Level I indicators conducted in 2003 and of Level II indicator surveys conducted between 2002 and 2004
more
Healthcare Waste Management Toolkit for Global Fund Practitioners and Policy Makers: Part A
The document introduces a simple classification, minimums standards and a registration form for Foreign Medical Teams (FMTs) that may provide surgical and trauma care arriving within the aftermath of a sudden onset disaster. These can serve as tools to improve the coordination of the foreign medical... team response, and be the reference for registration on arrival as well as a possible global registration mechanism similar to what exists for urban search and rescue teams
more
This guidance highlights tangible, evidence-based priority actions in health and WASH programs to achieve the Global Targets for nutrition. Throughout the guidance the importance of cross-sectoral collaboration within and outside the Red Cross Red Crescent Movement to holistically address nutrition ...is emphasised.
more
The goal of the draft global action plan is to ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them.